Apimeds Pharmaceuticals US, Inc. (APUS) — Stance & relative strength
APUS
Apimeds Pharmaceuticals US, Inc. · Healthcare · Pharmaceutical Products
$0.90▲+4.90%
Neutral · stance 47
TODAY'S READ · AS OF 2026-06-26
As of 2026-06-26, Apimeds Pharmaceuticals US, Inc. (APUS) has a 3-month relative strength percentile of 1 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 20. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 19.1%, relative volume 3.07×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
APUS ranks at the 5th percentile over 1 month, 1th percentile over 3 months, 2th percentile over 6 months, 3th percentile over 1 year against the full TickerStance CS+ADRC universe of U.S. equities.
APUS is classified under the Healthcare sector within the Pharmaceutical Products industry per the TickerStance sector-classification pipeline, which maps U.S. equities to GICS-aligned sectors using exchange SIC codes and Massive Finance reference data.
Sector RS percentile is not available for Healthcare at this snapshot. Leading sector status (threshold: Healthcare RS ≥ 70th percentile) cannot be determined until the next sector RS pipeline run.
APUS currently shows a 20-day average daily range (ADR%) of 19.1%, a 90-day beta versus the S&P 500 of -1.23. An ADR% above 4% indicates an intraday swing-trading eligible name in the Minervini Volatility Contraction Pattern framework. ADR% and ATR% are updated daily; beta is computed over a trailing 90-day window.
TickerStance computes APUS's month-by-month seasonality from its full daily price history: the average and median return for each calendar month, how often that month closed higher, and the best and worst months on record. These are historical frequencies, not forecasts — a strong seasonal month describes what APUS has tended to do in prior years, not a prediction of what comes next. The full month-by-month heatmap and win-rate table sit higher on this page.
APUS most recently filed a 10-Q covering FY26 Q1 with the SEC on 2026-05-26. TickerStance sources earnings data from SEC EDGAR XBRL submissions and updates the fundamentals panel daily. The Pro dossier shows eight quarters of EPS and revenue trend, operating margin history, and a composite earnings-quality rank.
§ Seasonality
Not enough history to compute monthly seasonality for APUS.